vs

Side-by-side financial comparison of INVESTORS TITLE CO (ITIC) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

INVESTORS TITLE CO is the larger business by last-quarter revenue ($69.5M vs $35.5M, roughly 2.0× RECURSION PHARMACEUTICALS, INC.). On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -1.6%). INVESTORS TITLE CO produced more free cash flow last quarter ($25.4M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 14.0%).

The Real Estate Title Insurance Company of Philadelphia was the world's first title insurance company.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

ITIC vs RXRX — Head-to-Head

Bigger by revenue
ITIC
ITIC
2.0× larger
ITIC
$69.5M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+683.3% gap
RXRX
681.7%
-1.6%
ITIC
More free cash flow
ITIC
ITIC
$72.7M more FCF
ITIC
$25.4M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
14.0%
ITIC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ITIC
ITIC
RXRX
RXRX
Revenue
$69.5M
$35.5M
Net Profit
$-108.1M
Gross Margin
59.8%
Operating Margin
13.8%
-304.8%
Net Margin
-304.2%
Revenue YoY
-1.6%
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$3.97
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ITIC
ITIC
RXRX
RXRX
Q4 25
$69.5M
$35.5M
Q3 25
$73.0M
$5.2M
Q2 25
$73.6M
$19.2M
Q1 25
$56.6M
$14.7M
Q4 24
$70.6M
$4.5M
Q3 24
$68.8M
$26.1M
Q2 24
$65.4M
$14.4M
Q1 24
$53.5M
$13.8M
Net Profit
ITIC
ITIC
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$12.2M
$-162.3M
Q2 25
$12.3M
$-171.9M
Q1 25
$3.2M
$-202.5M
Q4 24
$-178.9M
Q3 24
$9.3M
$-95.8M
Q2 24
$8.9M
$-97.5M
Q1 24
$4.5M
$-91.4M
Gross Margin
ITIC
ITIC
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
ITIC
ITIC
RXRX
RXRX
Q4 25
13.8%
-304.8%
Q3 25
20.7%
-3327.6%
Q2 25
21.5%
-916.8%
Q1 25
7.2%
-1297.9%
Q4 24
15.3%
-4042.4%
Q3 24
16.8%
-377.1%
Q2 24
17.2%
-697.4%
Q1 24
10.8%
-698.4%
Net Margin
ITIC
ITIC
RXRX
RXRX
Q4 25
-304.2%
Q3 25
16.7%
-3135.3%
Q2 25
16.7%
-894.2%
Q1 25
5.6%
-1373.3%
Q4 24
-3935.5%
Q3 24
13.5%
-367.5%
Q2 24
13.6%
-676.6%
Q1 24
8.5%
-662.4%
EPS (diluted)
ITIC
ITIC
RXRX
RXRX
Q4 25
$3.97
$-0.17
Q3 25
$6.45
$-0.36
Q2 25
$6.48
$-0.41
Q1 25
$1.67
$-0.50
Q4 24
$4.41
$-0.56
Q3 24
$4.92
$-0.34
Q2 24
$4.70
$-0.40
Q1 24
$2.40
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ITIC
ITIC
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$89.6M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$268.3M
$1.1B
Total Assets
$363.1M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ITIC
ITIC
RXRX
RXRX
Q4 25
$89.6M
$743.3M
Q3 25
$110.8M
$659.8M
Q2 25
$90.1M
$525.1M
Q1 25
$81.7M
$500.5M
Q4 24
$83.8M
$594.4M
Q3 24
$112.9M
$427.6M
Q2 24
$111.2M
$474.3M
Q1 24
$135.0M
$296.3M
Total Debt
ITIC
ITIC
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
ITIC
ITIC
RXRX
RXRX
Q4 25
$268.3M
$1.1B
Q3 25
$278.0M
$1.0B
Q2 25
$266.2M
$919.1M
Q1 25
$254.4M
$933.9M
Q4 24
$251.8M
$1.0B
Q3 24
$271.3M
$524.6M
Q2 24
$261.8M
$584.4M
Q1 24
$254.0M
$401.2M
Total Assets
ITIC
ITIC
RXRX
RXRX
Q4 25
$363.1M
$1.5B
Q3 25
$363.3M
$1.4B
Q2 25
$345.8M
$1.3B
Q1 25
$333.8M
$1.3B
Q4 24
$333.6M
$1.4B
Q3 24
$352.0M
$726.5M
Q2 24
$340.3M
$775.9M
Q1 24
$329.5M
$557.8M
Debt / Equity
ITIC
ITIC
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ITIC
ITIC
RXRX
RXRX
Operating Cash FlowLast quarter
$30.9M
$-46.1M
Free Cash FlowOCF − Capex
$25.4M
$-47.3M
FCF MarginFCF / Revenue
36.5%
-133.1%
Capex IntensityCapex / Revenue
8.0%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$47.1M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ITIC
ITIC
RXRX
RXRX
Q4 25
$30.9M
$-46.1M
Q3 25
$17.2M
$-117.4M
Q2 25
$8.9M
$-76.4M
Q1 25
$-75.0K
$-132.0M
Q4 24
$29.8M
$-115.4M
Q3 24
$7.8M
$-59.2M
Q2 24
$8.4M
$-82.2M
Q1 24
$1.4M
$-102.3M
Free Cash Flow
ITIC
ITIC
RXRX
RXRX
Q4 25
$25.4M
$-47.3M
Q3 25
$15.8M
$-117.6M
Q2 25
$7.3M
$-79.6M
Q1 25
$-1.4M
$-133.8M
Q4 24
$22.4M
$-116.7M
Q3 24
$6.1M
$-63.8M
Q2 24
$6.3M
$-83.4M
Q1 24
$-793.0K
$-109.0M
FCF Margin
ITIC
ITIC
RXRX
RXRX
Q4 25
36.5%
-133.1%
Q3 25
21.7%
-2272.5%
Q2 25
9.9%
-413.9%
Q1 25
-2.5%
-907.4%
Q4 24
31.7%
-2567.7%
Q3 24
8.8%
-244.6%
Q2 24
9.7%
-578.5%
Q1 24
-1.5%
-789.9%
Capex Intensity
ITIC
ITIC
RXRX
RXRX
Q4 25
8.0%
3.5%
Q3 25
1.8%
4.7%
Q2 25
2.1%
16.4%
Q1 25
2.4%
12.4%
Q4 24
10.5%
28.6%
Q3 24
2.5%
17.5%
Q2 24
3.2%
8.2%
Q1 24
4.2%
48.2%
Cash Conversion
ITIC
ITIC
RXRX
RXRX
Q4 25
Q3 25
1.40×
Q2 25
0.72×
Q1 25
-0.02×
Q4 24
Q3 24
0.84×
Q2 24
0.95×
Q1 24
0.32×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons